diaDexus moves CAD (coronary artery disease) risk test closer to the US:
This article was originally published in Clinica
diaDexus is pushing ahead with efforts to market in the US its PLAC blood test for predicting coronary artery disease (CAD) risk, after submitting a 510(k) application for the product to the FDA. The test provides a quantitative measurement of lipoprotein-associated phospholipase A2, or Lp-PLA2, a marker believed to be a risk factor for coronary heart disease. Since a significant proportion of individuals who suffer a heart attack have no previous signs or symptoms of coronary heart disease, such as elevated cholesterol, there is clearly a need for additional tests to accurately identify those at risk, says Patrick Plewman, the San Francisco, California's firm's CEO.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.